SLC2A1 and Dravet syndrome: Very recently two interesting studies employing dual targeting hCAIs for the treatment of diverse neurological diseases, i.e., oxaliplatin-induced neuropathy (OINP) and Glucose Transporter Type 1 Deficiency Syndrome (GLUT1-DS), were reported by Angeli et al. (2023a, 2023b).